Dual Purpose of a Cell-Based Assay for an Agonist of the GLP-2 Receptor
Development of an Oligonucleotide Drug Immunogenicity Assay: A Case for the Characterization of the Immune Response
The Many Faces of Recreational Drug Use: A New Podcast Series
Prescription drug abuse is a serious public health concern that has been exacerbated by the stress of living through the COVID-19 pandemic. Behind this troubling trend are individual people, each with their own story to share.
Altasciences recently launched a podcast series, The Many Faces of Recreational Drug Use, to provide insight into the personal experiences of individuals who abuse opioids and stimulants. Hosted by Altasciences’ Chief Scientific Officer, Dr. Beatrice Setnik, with expert commentary by Psychiatrist and Senior Principal Investigator, Dr. Debra Kelsh, the first episode provides a candid discussion of some of the hopes and challenges experienced by those who struggle with drug abuse.
Speak with an expert about your research needs.
You may also be interested in the following:
- Webpage: Human Abuse Potential
- Webinar: Navigating Early Phase CNS-Active Drug Development
- The Altascientist: CNS-Active Drugs – Complex Considerations
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Moving Your Drug Forward to Preclinical Trials
Your drug discovery phase is nearing completion and your funding is in place. What comes next?
Five Ways Altasciences Simplifies the Drug Development Process for You
Bringing new drugs to market, from lead candidate selection through preclinical testing, to clinical proof of concept, is a complex, time-consuming, and costly process.
Contract Pharma: Altasciences Continues Expansion with Additional Facilities in Philadelphia
September 2021
In this issue
Complimentary webinars and podcasts, thought-provoking articles, industry news, and more!
Mitigate risks with a stepwise approach to first-in-human trials.
Five Ways Altasciences Simplifies the Drug Development Process for You
Discover how Altasciences relieves you of the need to plan and manage the many elements of early phase drug development, for hassle-free outsourcing.
Benefits of Using Liquid-Filled Capsules in Clinical Trials
Discover why two-piece, liquid-filled, hard-shell capsules (LFCs) are the solution formulation scientists are looking to for turning poorly soluble small molecules into viable development candidates.
Emyria Limited Partners with Altasciences to Accelerate FDA and TGA CBD Registration
Read this article to learn more about the partnership, which could lead to the first over-the-counter CBD medicine available in Australia.
Calvert Labs, an Altasciences Company, has been selected to design and conduct exploratory studies for Tryp’s Psilocybin-for-Neuropsychiatric Disorders (PRNTM) program.
New Podcast Series: “The Many Faces of Recreational Drug Use”
The series is a collection of candid conversations with study participants about their personal drug use history, both with recreational drug use and with substance use disorder. Throughout the conversations, Altasciences’ Dr. Beatrice Setnik, Chief Scientific Officer, and Dr. Debra Kelsh, MD, Senior Principal Investigator and Psychologist, pause to discuss key moments in the interviews. Watch the first episode!
In September, Altasciences began a six-month Phase I relative bioavailability study for AL001 for dementia related to Alzheimer’s disease. The objective of the first-in-human study is to determine the safety, tolerability, and appropriate dosing for future studies.
Altasciences’ Chief Scientific Officer, Dr. Beatrice Setnik, Contributes to a Study on Difelikefalin
This article for the journal Clinical and Translational Science, co-authored by Dr. Setnik, shares the findings of a study that assessed the effect of difelikefalin, a selective kappa opioid receptor agonist designed to limit central nervous system (CNS) penetration, on key relevant measures of respiratory depression in healthy volunteers.
CONTINUE READING
- Webinars
Catch up on some of our favorite on-demand webinars. - Podcasts
Listen to (or watch) our discussions on drug development topics, including an interview with Dr. John Atkinson, Founder of Atkinson Toxicology Consulting, the first episode of “The Many Faces of Recreational Drug Use” series, and a discussion on developing the second generation of psychedelics and their analogs for targeted medical use. - Up Close and Personal With…
Meet Ben Reed, BS, Vice President of Operations for Altasciences’ Manufacturing and Analytical Services. - Blog
Catch up on Altasciences’ latest blog articles on microsampling, ethnobridging, and liquid-filled capsules. - Upcoming Events
See what events we will be attending over the next few weeks.
Are You Using the Right Dosage Form for Your API?
Applications of Liquid-Filled Capsules for Challenging APIs in Pharmaceutical Manufacturing
Liquid-filled, hard-shell capsules (LFCs) offer significant benefits for APIs that present formulation or manufacturing challenges. They are also an attractive option for sustained release products, line extensions, and brand differentiation. Their use is beneficial throughout the different phases of drug development, from preclinical to commercialization.
Download our white paper to learn more on the process of liquid-filled capsule manufacturing, and to find out if LFCs are the right choice for your API.
You may also be interested in the following:
- Webpage: Pharmaceutical Contract Manufacturing and Analytical Services
- Video: Benefits of Liquid-Filled Capsule Manufacturing
- Webpage: Comprehensive Clinical Trial Services
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.